Sector: Health Care
Director information for WEST PHARMACEUTICAL SERVICES INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| DEBORAH L. V. KELLER | Former Chief Executive Officer, Covance Drug Development | 63 | ["Broad international healthcare industry experience","Leadership as CEO of Covance Drug Development","Experience marketing to customers","International executive leadership experience","Regulatory and Quality Assurance experience in drug development and manufacturing"] | ["CC","Nominating & Corporate Governance","Compensation"] | 2026 |
| DOUGLAS A. MICHELS | Retired President & Chief Executive Officer, OraSure Technologies, Inc. | 69 | ["More than 30 years of experience in the healthcare diagnostics industry","Chief Executive Officer of OraSure Technologies (2004–2018)","Earlier roles at Johnson & Johnson (1985–2004)","Experience in leading global operations and navigating complex regulatory processes","Background in strategy, supply-chain management and product development"] | ["NCGC","Audit","Nominating & Corporate Governance","Audit Committee"] | 2026 |
| ERIC M. GREEN | President and Chief Executive Officer, West Pharmaceutical Services, Inc.; Chair of the Board; Director; PEO | 56 | ["Comprehensive healthcare industry experience","Leadership as Chief Executive Officer of West","Prior senior executive roles at Sigma-Aldrich","Expertise in innovation, operations and global business transformation","Experience managing large-scale operations and business strategy","Direct insight into corporate strategy, risk management and performance oversight"] | [] | 2026 |
| JANET B. HAUGEN | Retired Chief Financial Officer, Unisys Corporation; Chair | 67 | ["Extensive financial and executive leadership experience","Served as Chief Financial Officer at Unisys Corporation for 16 years","Expertise in business transformation, finance and corporate administration","Broad industry knowledge developed as a senior executive in a global technology organization","Partner at Ernst & Young, working with Fortune 500 companies","Experience in auditing, risk management, corporate governance, financial controls and corporate management","Audit Committee Financial Expert"] | ["Audit","Audit Committee"] | 2026 |
| MARK A. BUTHMAN | Retired Executive Vice President & Chief Financial Officer, Kimberly-Clark Corporation; Former Executive Vice President & Chief Financial Officer | 65 | ["extensive global financial expertise","deep knowledge of branded products within consumer, professional and healthcare sectors","Senior Vice President and Chief Financial Officer at Kimberly-Clark Corporation","financial management skills acquired during 33-year career at Kimberly-Clark","experience serving as Chair of the Audit Committee at IDEX Corporation","strategic planning insights with a track record of more than 50 acquisitions totaling over $10 billion"] | ["AC","Compensation Committee"] | 2026 |
| MOLLY E. JOSEPH | Former Chief Executive Officer, UnitedHealthcare Global | 52 | ["Extensive international healthcare industry experience","Managed operations for 55 hospitals and several hundred ambulatory centers","Expertise in financial management, health-system delivery and funding, and global health systems","More than two decades of mergers and acquisitions experience","Former Chief Executive Officer of UnitedHealthcare Global","Founder and Managing Partner of Cypress Pass Ventures","Senior Advisor of Invidia Capital Management LP"] | ["NCGC","Compensation","Nominating & Corporate Governance"] | 2026 |
| Myla P. Lai-Goldman | [] | ["Audit Committee"] | 2026 | ||
| MYLA P. LAI-GOLDMAN, M.D. | Chair and Former Chief Executive Officer and President, GeneCentric Therapeutics, Inc. | 68 | ["expansive healthcare industry experience","senior leadership roles at GeneCentric Therapeutics","senior leadership roles at Labcorp","senior leadership roles at Roche Biomedical","managing partner of Personalized Science, LLC","board-certified anatomic and clinical pathologist","regulatory, research and product development experience","Chief Medical Officer at Labcorp"] | ["Audit Committee"] | 2026 |
| Paolo Pucci | Retired Chief Executive Officer, ArQule, Inc. | 64 | ["Extensive global healthcare and biopharmaceutical experience","Chief Executive Officer of ArQule (2008–2020)","Executive roles at Bayer A.G. (2001–2008)","Expertise in strategic planning, capital allocation, and operational oversight","Experience in managing global pharmaceutical operations and regulatory affairs","Public company CEO and director of multiple international life-sciences companies"] | ["Audit Committee"] | 2026 |
| PAOLO PUCCIR | Retired Chief Executive Officer, ArQule, Inc. | 64 | [] | [] | 2026 |
| ROBERT F. FRIEL | Retired Chair, President & Chief Executive Officer, PerkinElmer, Inc. (now Revvity, Inc.); Lead Independent Director; Chair of the Board of Directors | 70 | ["Retired Chair, President & Chief Executive Officer, PerkinElmer, Inc.","Comprehensive healthcare industry experience","Leadership in setting growth strategy and overseeing operational and financial risks","Finance and tax expertise","Experience with mergers, acquisitions and strategic partnerships","Service on other Boards"] | ["CC","Nominating & Corporate Governance"] | 2026 |
| STEPHEN H. LOCKHART, M.D., PH.D. | Former Chief Medical Officer, Sutter Health | 67 | ["Extensive healthcare leadership experience","Created a regulatory framework for drug testing and drug development in precision medicine","Served on the California Governor’s Advisory Committee on Precision Medicine","Significant business development experience managing mergers of hospital systems","Board-certified anesthesiologist","Deep financial knowledge and operational experience"] | ["Compensation"] | 2026 |
| Thomas W. Hofmann | Chair of the Audit Committee | [] | [] | 2026 | |
| William F. Feehery | [] | [] | 2026 | ||
| WILLIAM F. FEEHERY, PH.D. | Former Chief Executive Officer, Certara, Inc. | 56 | ["Former Chief Executive Officer of Certara","Significant experience in managing R&D and commercializing cutting-edge technologies","Experience leading multiple business units at DuPont","Financial and strategic acumen"] | ["Audit"] | 2026 |
